Search Medical Condition
Please enter condition
Please choose location from dropdown

Addenbrooke's Hospital, Cambridge, United Kingdom Clinical Trials

A listing of Addenbrooke's Hospital, Cambridge, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (218) clinical trials

Adaprev in Digital Flexor Tendon Repair

This study is being undertaken to verify the safety and performance of Adaprev™, a Class III medical device, when administered as a short term implant into the tendon sheath at the time of surgery, on the post-operative function of severed digital tendons. Subjects are randomised to either Adaprev or standard ...

Phase N/A

0.0 miles

Learn More »

Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

ARM 1 - 10 prepubertal, 12-17 years old boys with no prior exposure to TRT will receive single dose of 5.5 mg on day one and single dose of 11 mg on day 2 with repeat blood draws to assess serum levels of testosterone and metabolites. ARM 2 - 10 ...

Phase

0.02 miles

Learn More »

Efficacy Safety Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation

This is a phase 2 study to evaluate the efficacy, safety, tolerability and pharmacokinetics of GSK1070806 in subjects undergoing renal transplantation. GSK1070806 is an anti-interleukin 18 (IL18) monoclonal antibody, which binds to IL-18 and inhibits signaling through the IL-18 receptor. Recipients of donor kidneys, retrieved after circulatory death of the ...

Phase

0.03 miles

Learn More »

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

MyeChild 01 is an international phase III clinical trial in children with acute myeloid leukaemia (AML) a disease with significant mortality. It will compare two induction chemotherapy regimens: mitoxantrone and cytarabine (current standard treatment) with liposomal daunorubicin and cytarabine. This will test liposomal daunorubicin, which is believed to be less ...

Phase

0.03 miles

Learn More »

Dose Finding Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for ...

Phase

0.03 miles

Learn More »

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies neoGAA and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

The duration of the study per patient will be up to 3 years that will consist of a 14- day screening period (may be extended up to 8 weeks in pre-specified situations), a 49-week blinded treatment period, a 96-week open-label treatment period, and a 4-week post-treatment observation period.

Phase

0.03 miles

Learn More »

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

This is a randomized, double blind, active control study of PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients treated for approximately 1 year with agalsidase beta and on a stable dose for at least 6 months will be screened and then randomized to continue treatment with ...

Phase

0.03 miles

Learn More »

A Study of CA-170 (Oral PD-L1 PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results in activation of T cell proliferation and cytokine production. This is a multi-center, open-label, Phase 1 trial ...

Phase

0.03 miles

Learn More »

Study Evaluating CERAMENT |G in Open Diaphyseal Tibial Fractures

CERAMENT|G is a resorbable, gentamicin containing ceramic bone graft indicated to fill bony voids or gaps which are not intrinsic to the stability of the bony structure and where there is risk of bacterial contamination.

Phase N/A

0.03 miles

Learn More »

GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3

The total duration for GD1 patients is 45 days (Part 1), while for GD3 patients, the total duration is up to 168 weeks, including 2 part-treatment of 52 weeks and 104 weeks, respectively.

Phase

0.03 miles

Learn More »